In Plain English
Your pituitary has two separate switches for releasing growth hormone. CJC-1295 presses one, Ipamorelin presses the other. Pressing both produces a larger release than pressing either alone — and because you are prompting your own gland rather than injecting growth hormone directly, the body’s normal feedback controls stay in place.
What people use it for. Recovery, sleep quality, body composition and general wellbeing. It is the standard entry point into the growth hormone category and the most widely used blend of its type.
What to know before you buy. Dose it at night, away from food. The reasoning is straightforward: your biggest natural growth hormone pulse happens in early deep sleep, so the goal is to amplify that rather than fight against it, and food raises insulin, which blunts the release. If you want an objective read on whether it is doing anything, IGF-1 on a blood panel is the marker — it reflects growth hormone exposure over time far better than a single growth hormone reading.
What It's Used For
| Goal | What that rests on |
|---|---|
| Recovery and repair | Two separate GH pathways engaged together; the best mechanistic rationale of any blend here |
| Sleep quality | Dosed at night to amplify your largest natural GH pulse in early deep sleep |
| Body composition | The most common reason people start; reliably raises GH and IGF-1 |
| Measurable | IGF-1 on a standard blood panel tells you objectively whether it is working |
The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.
Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. Free shipping on every order, no minimum. Third-party COA available for every batch — HPLC purity and mass spec verification.
Reconstitution — bacteriostatic water: 5mg + 5mg vial at 2mL = 5mg/mL, so 10 units on a 100-unit syringe draws 0.5mg. Concentrations are arithmetic from vial content and diluent volume, not a dosing recommendation.
Most vendors sell these as two separate SKUs and charge for both — commonly $117 to $146 for the pair, plus two reconstitutions. This is one vial at $75.
Text To OrderAt a Glance
- Components
- CJC-1295 without DAC (mod GRF 1-29) and Ipamorelin, typically 5mg + 5mg
- Rationale
- CJC-1295 acts on the GHRH receptor; Ipamorelin acts on the ghrelin receptor. Separate pathways, additive signal
- Why no DAC
- The short-acting form preserves pulsatile release rather than producing sustained elevation
- Typical timing
- Commonly dosed at night, to align with the body’s largest natural GH pulse during early deep sleep
- Regulatory (US)
- Neither component is FDA-approved. Neither was on the July 2026 PCAC agenda
- Format
- 5+5mg vial
Regulatory status
Neither CJC-1295 nor Ipamorelin was on the July 2026 PCAC agenda. Their regulatory status is unchanged by that hearing and should not be conflated with the six peptides that were recommended. Neither is FDA-approved and neither is on the 503A bulks list.
How the Components Compare
| Component | What it adds | What it does not do |
|---|---|---|
| CJC-1295 (no DAC) | Acts on the GHRH receptor. Extends the amplitude of the growth hormone pulse | Does not touch the ghrelin pathway, so alone it leaves half the available signal unused |
| Ipamorelin | Acts on the ghrelin receptor — a genuinely separate pathway, which is why the two add rather than overlap. Selective, so minimal cortisol or prolactin effect | Does not engage the GHRH receptor. Alone it produces a smaller release than the pair |
Why the Combination Makes Sense
This is one of the few blends in the range where the combination rationale rests on established receptor pharmacology rather than inference. GHRH receptor agonism and ghrelin receptor agonism are genuinely distinct mechanisms, and their combined effect on GH release is well described in the pharmacological literature.
Night dosing is the common convention because the largest natural GH pulse occurs during early deep sleep, and the intent is to amplify that existing pulse rather than create an unnatural one. Dosing away from food is conventional practice, on the reasoning that elevated insulin and blood glucose blunt GH release.
What Is Not Established
The combination reliably raises growth hormone and IGF-1. It has not been shown in controlled outcome trials to produce meaningful improvements in body composition, recovery, sleep quality or healthspan in healthy adults. That gap between biomarker change and clinical benefit is the honest framing for this category.
IGF-1 is the practical monitoring marker if you want an objective read on whether a protocol is doing anything measurable, since it integrates GH exposure over time far better than a spot GH measurement can.
The bottom line
The best mechanistic rationale of any blend in this range, built on two well-characterised and genuinely separate receptor pathways. Demonstrated effect on GH and IGF-1; no demonstrated outcome benefit. Its regulatory status is independent of the July 2026 hearing.